Exagen Inc (XGN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $105.37M
Last updated: Nov 17, 2026 at 11:06 AM ET
Exagen Inc (XGN) Earnings: Report Dates and Results
Exagen (XGN) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Exagen reported EPS of -$0.25, below the -$0.19 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
XGN has an expected report date of Mar 8, 2027.
XGN Earnings Call
The latest XGN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 29 quarters below that had an estimate, XGN beat 20, missed 7 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $18.42M, up 6.8% from $17.24M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.25 | -$0.19 | N/A | -31.58% | Miss | N/A | 2 | 0 up, 1 down | Nov 10, 2026 | $18.42M |
| Jun 30, 2026 | -$0.13 | -$0.19 | N/A | +31.58% | Beat | N/A | 1 | N/A | Aug 4, 2026 | $19.94M |
| Mar 31, 2026 | -$0.20 | -$0.25 | -$0.25 - -$0.25 | +20.00% | Beat | N/A | 2 | 1 up, 2 down | May 11, 2026 | $17.31M |
| Dec 31, 2025 | -$0.27 | -$0.18 | -$0.23 - -$0.17 | -48.80% | Miss | N/A | 6 | 0 up, 3 down | Mar 10, 2026 | $16.63M |
| Sep 30, 2025 | -$0.31 | -$0.16 | -$0.18 - -$0.14 | -93.75% | Miss | N/A | 4 | 0 up, 1 down | Nov 4, 2025 | $17.24M |
| Jun 30, 2025 | -$0.18 | -$0.15 | -$0.18 - -$0.12 | -20.00% | Miss | N/A | 5 | 0 up, 3 down | Jul 29, 2025 | $17.20M |
| Mar 31, 2025 | -$0.20 | -$0.21 | -$0.23 - -$0.19 | +4.76% | Beat | N/A | 3 | 2 up, 1 down | May 5, 2025 | $15.50M |
| Dec 31, 2024 | -$0.20 | -$0.24 | -$0.30 - -$0.10 | +16.67% | Beat | N/A | 5 | 1 up, 1 down | Mar 11, 2025 | $13.65M |
| Sep 30, 2024 | -$0.28 | -$0.28 | -$0.32 - -$0.26 | 0.00% | In line | N/A | 6 | 0 up, 0 down | Nov 12, 2024 | $12.51M |
| Jun 30, 2024 | -$0.16 | -$0.35 | -$0.37 - -$0.29 | +54.29% | Beat | N/A | 6 | 1 up, 0 down | Aug 5, 2024 | $15.06M |
| Mar 31, 2024 | -$0.19 | -$0.35 | -$0.40 - -$0.32 | +45.71% | Beat | N/A | 6 | 0 up, 0 down | May 13, 2024 | $14.41M |
| Dec 31, 2023 | -$0.31 | -$0.43 | -$0.48 - -$0.39 | +27.91% | Beat | N/A | 6 | 0 up, 0 down | Mar 18, 2024 | $13.77M |
| Sep 30, 2023 | -$0.31 | -$0.49 | -$0.50 - -$0.36 | +36.73% | Beat | N/A | 6 | 0 up, 0 down | Nov 13, 2023 | $13.42M |
| Jun 30, 2023 | -$0.28 | -$0.49 | -$0.53 - -$0.47 | +42.86% | Beat | N/A | 6 | 0 up, 0 down | Aug 7, 2023 | $14.14M |
| Mar 31, 2023 | -$0.44 | -$0.56 | -$0.61 - -$0.49 | +21.43% | Beat | N/A | 6 | 0 up, 0 down | May 15, 2023 | $11.23M |
| Dec 31, 2022 | -$0.83 | -$0.78 | -$0.81 - -$0.71 | -6.41% | Miss | N/A | 6 | 0 up, 0 down | Mar 20, 2023 | $12.84M |
| Sep 30, 2022 | -$0.47 | -$0.76 | -$0.80 - -$0.58 | +38.16% | Beat | N/A | 6 | 1 up, 0 down | Nov 14, 2022 | $14.73M |
| Jun 30, 2022 | -$0.78 | -$0.57 | N/A | -36.84% | Miss | N/A | N/A | 0 up, 0 down | Aug 4, 2022 | $7.61M |
| Mar 31, 2022 | -$0.60 | -$0.61 | -$0.64 - -$0.55 | +1.64% | Beat | N/A | 6 | 0 up, 0 down | May 11, 2022 | $10.39M |
| Dec 31, 2021 | -$0.42 | -$0.50 | -$0.61 - -$0.35 | +16.00% | Beat | N/A | 6 | 0 up, 0 down | Mar 22, 2022 | $12.69M |
| Sep 30, 2021 | -$0.42 | -$0.47 | -$0.56 - -$0.39 | +10.64% | Beat | N/A | 6 | N/A | Nov 10, 2021 | $12.25M |
| Jun 30, 2021 | -$0.38 | -$0.44 | -$0.59 - -$0.37 | +13.64% | Beat | N/A | 6 | N/A | Aug 9, 2021 | $12.77M |
| Mar 31, 2021 | -$0.48 | -$0.48 | -$0.55 - -$0.41 | 0.00% | In line | N/A | 6 | N/A | May 11, 2021 | $10.59M |
| Dec 31, 2020 | -$0.27 | -$0.41 | -$0.45 - -$0.33 | +34.15% | Beat | N/A | 5 | N/A | Mar 16, 2021 | $12.67M |
| Sep 30, 2020 | -$0.34 | -$0.47 | -$0.54 - -$0.45 | +27.66% | Beat | N/A | 4 | N/A | Nov 10, 2020 | $10.78M |
| Jun 30, 2020 | -$0.27 | -$0.79 | -$0.82 - -$0.68 | +65.82% | Beat | N/A | 3 | N/A | Jul 28, 2020 | $8.95M |
| Mar 31, 2020 | -$0.44 | -$0.56 | -$0.63 - -$0.34 | +21.43% | Beat | N/A | 3 | N/A | May 11, 2020 | $9.58M |
| Dec 31, 2019 | -$0.27 | -$0.37 | -$0.40 - -$0.33 | +27.03% | Beat | N/A | 3 | N/A | Mar 25, 2020 | $10.21M |
| Sep 30, 2019 | -$11.29 | -$2.40 | -$4.22 - -$0.58 | -370.42% | Miss | N/A | 2 | N/A | Nov 12, 2019 | $10.44M |
| Jun 30, 2019 | -$1.60 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 20, 2019 | $10.47M |
| Mar 31, 2015 | -$0.27 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2015 | $4.37M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.96, after -$0.83 the year before. It was -$13.43 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.96 | N/A |
| Dec 31, 2024 | -$0.83 | N/A |
| Dec 31, 2023 | -$1.34 | N/A |
| Dec 31, 2022 | -$2.68 | N/A |
| Dec 31, 2021 | -$1.70 | N/A |
| Dec 31, 2020 | -$1.32 | N/A |
| Dec 31, 2019 | -$13.43 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,200 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,230 | 11 | |
| 2026Q2 | Jun 30, 2026 | 6,171 | 10 | |
| 2026Q1 | Mar 31, 2026 | 6,344 | 9 | |
| 2025Q3 | Sep 30, 2025 | 8,024 | 11 | |
| 2025Q2 | Jun 30, 2025 | 5,786 | 8 | |
| 2025Q1 | Mar 31, 2025 | 7,385 | 9 | |
| 2024Q4 | Dec 31, 2024 | 7,241 | 10 | |
| 2024Q3 | Sep 30, 2024 | 7,613 | 9 |
2026Q3 Earnings Call
Opening remarks
Tina Jacobsen Head of Investor Relations Thanks, operator. Good morning, and thank you for joining us to discuss Exagen's financial results for the quarter ended September 30, 2026. Today, I'm joined by John Aballi, our President and Chief Executive Officer, and Jeff Black, our Chief Financial Officer. The recording of this call, the press release announcing our financial results, and the slide presentation can be accessed on our website at www.exagen.com. Today's call will include forward-looking statements. We encourage you to review the statements contained in today's press release and the risks and uncertainties described in our SEC filings, which identify certain factors that may cause the company's actual events, performance, and results to differ materially from those contained in the forward-looking statements made on today's call. We also will discuss non-GAAP financial measures on this call. Descriptions of these non-GAAP financial measures and the reconciliations of GAAP to non-GAAP financial measures are included in today's press release. And now I will turn the call over to John Aballi. John?
John Aballi President and Chief Executive Officer Good morning, everyone, and thank you for joining us. The third quarter extended what is fast becoming a record year for Exagen, with execution toward our vision increasingly evident in the results. I'll get right into the details. This morning, we reported third quarter revenue of $18.4 million, the best third quarter in company history. Year-to-date, revenue has grown more than 11%, which has contributed to an adjusted EBITDA improvement of over 30%. We grew both volume and price compared to last year. Trailing 12-month ASP reached a new record of $451, marking our 14th consecutive quarter of improvement. That speaks to the durability of our growth, and we're confidently reiterating full-year revenue guidance of $72 million to $75 million. During the quarter, we utilized our ATM facility to strengthen the balance sheet and opportunistically brought in high-caliber investors as we continue to build and shape the company for the long term. We're really pleased to have their support. As always, our mission is at the heart of everything we do. Autoimmune disease is diagnosed too late and too inconsistently, and it's the patients who suffer. This is why Exagen exists, and we are singularly focused on building a unique platform to bring clarity to these complex diseases. I spent a good amount of time in the field with customers over the last few months, and the conversations I had reinforced the critical nature of our work and the strategic path we're taking. I visited with customers here in Southern California, Louisiana, and New York to discuss our offerings, how we can better support their practices, and to preview new products that will address important diagnostic challenges.
Frequently Asked Questions About XGN
When is Exagen's next earnings date?
Exagen's next earnings report is expected for Mar 8, 2027.
Did XGN beat earnings estimates last quarter?
No. Exagen reported EPS of -$0.25 for the quarter ended Sep 30, 2026, below the -$0.19 estimate by 31.58%.
What EPS do analysts expect from XGN next quarter?
The consensus EPS estimate for Exagen for the quarter ending Dec 31, 2026 is -$0.19 from 9 analysts, with estimates from -$0.21 to -$0.17.
How often does XGN beat earnings estimates?
Exagen beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -15.14%.
XGN pages: Overview, Earnings, Forecast, Financials, Competitors